M. Brawner Floyd

7.7k total citations · 1 hit paper
41 papers, 2.3k citations indexed

About

M. Brawner Floyd is a scholar working on Organic Chemistry, Molecular Biology and Oncology. According to data from OpenAlex, M. Brawner Floyd has authored 41 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Organic Chemistry, 12 papers in Molecular Biology and 11 papers in Oncology. Recurrent topics in M. Brawner Floyd's work include HER2/EGFR in Cancer Research (9 papers), Quinazolinone synthesis and applications (9 papers) and Synthesis and biological activity (5 papers). M. Brawner Floyd is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Quinazolinone synthesis and applications (9 papers) and Synthesis and biological activity (5 papers). M. Brawner Floyd collaborates with scholars based in United States and Canada. M. Brawner Floyd's co-authors include Bernard D. Johnson, Allan Wissner, Ramaswamy Nilakantan, Ru Shen, Hwei‐Ru Tsou, Marvin F. Reich, Sridhar K. Rabindran, Carolyn Discafani, Yu‐Fen Wang and William Hallett and has published in prestigious journals such as Journal of the American Chemical Society, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

M. Brawner Floyd

40 papers receiving 2.2k citations

Hit Papers

Antitumor Activity of HKI-272, an Orally Active, Irrevers... 2004 2026 2011 2018 2004 100 200 300 400 500

Peers

M. Brawner Floyd
Marvin F. Reich United States
Hwei‐Ru Tsou United States
Dennis J. McNamara United States
Karen Lackey United States
Scott H. Dickerson United States
Giorgio Caravatti Switzerland
Gregory D. Vite United States
Carolyn Discafani United States
Wilson B. Knight United States
Marvin F. Reich United States
M. Brawner Floyd
Citations per year, relative to M. Brawner Floyd M. Brawner Floyd (= 1×) peers Marvin F. Reich

Countries citing papers authored by M. Brawner Floyd

Since Specialization
Citations

This map shows the geographic impact of M. Brawner Floyd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Brawner Floyd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Brawner Floyd more than expected).

Fields of papers citing papers by M. Brawner Floyd

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Brawner Floyd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Brawner Floyd. The network helps show where M. Brawner Floyd may publish in the future.

Co-authorship network of co-authors of M. Brawner Floyd

This figure shows the co-authorship network connecting the top 25 collaborators of M. Brawner Floyd. A scholar is included among the top collaborators of M. Brawner Floyd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Brawner Floyd. M. Brawner Floyd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wodicka, Lisa, Pietro Ciceri, Mindy I. Davis, et al.. (2010). Activation State-Dependent Binding of Small Molecule Kinase Inhibitors: Structural Insights from Biochemistry. Chemistry & Biology. 17(11). 1241–1249. 82 indexed citations
2.
Nittoli, Thomas, Russell G. Dushin, M. Brawner Floyd, et al.. (2009). The identification of 8,9-dimethoxy-5-(2-aminoalkoxy-pyridin-3-yl)-benzo[c][2,7]naphthyridin-4-ylamines as potent inhibitors of 3-phosphoinositide-dependent kinase-1 (PDK-1). European Journal of Medicinal Chemistry. 45(4). 1379–1386. 21 indexed citations
3.
Wissner, Allan, Russell G. Dushin, M. Brawner Floyd, et al.. (2007). Dual irreversible kinase inhibitors: Quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. Bioorganic & Medicinal Chemistry. 15(11). 3635–3648. 62 indexed citations
4.
Tsou, Hwei‐Ru, William Hallett, Marvin F. Reich, et al.. (2005). Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity. Journal of Medicinal Chemistry. 48(4). 1107–1131. 246 indexed citations
5.
Berger, Dan, Minu Dutia, Dennis Powell, et al.. (2003). Synthesis and evaluation of 4-Anilino-6,7-dialkoxy-3-quinolinecarbonitriles as inhibitors of kinases of the Ras-MAPK signaling cascade. Bioorganic & Medicinal Chemistry Letters. 13(18). 3031–3034. 25 indexed citations
7.
Wissner, Allan, M. Brawner Floyd, Sridhar K. Rabindran, et al.. (2002). Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents. Bioorganic & Medicinal Chemistry Letters. 12(20). 2893–2897. 54 indexed citations
9.
Wang, Yanong D., Karen Miller, Diane H. Boschelli, et al.. (2000). Inhibitors of Src tyrosine kinase: the preparation and structure–activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines. Bioorganic & Medicinal Chemistry Letters. 10(21). 2477–2480. 58 indexed citations
10.
Discafani, Carolyn, Marion L. Carroll, M. Brawner Floyd, et al.. (1999). Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with In Vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785). Biochemical Pharmacology. 57(8). 917–925. 84 indexed citations
11.
Birnbaum, Jay E., Peter Cervoni, Peter S. Chan, et al.. (1982). Prostaglandins and congeners. 29. (16RS)-(.+-.)-15-Deoxy-16-hydroxy-16-vinylprostaglandin E2, an orally and transdermally active hypotensive agent of prolonged duration. Journal of Medicinal Chemistry. 25(5). 492–494. 15 indexed citations
12.
Floyd, M. Brawner & Martin J. Weiss. (1979). Prostaglandins and congeners. 21. Synthesis of some cyclohexyl analogs (11.alpha.-homoprostaglandins). The Journal of Organic Chemistry. 44(1). 71–75. 14 indexed citations
14.
Floyd, M. Brawner. (1978). Prostaglandins and congeners. 18. Synthesis of cyclopentenolone precursors to prostaglandins from 2,5-dihydro-2,5-dimethoxyfurans. The Journal of Organic Chemistry. 43(9). 1641–1643. 22 indexed citations
15.
Floyd, M. Brawner. (1974). A Synthesis of 2-(6′-Carboxy-2′-cis-Hexenyl)-4-Hydroxycyclopent-2-EN-1-ONE, a Prostagiandin Intermediate1. Synthetic Communications. 4(6). 317–323. 12 indexed citations
16.
Floyd, M. Brawner & Martin J. Weiss. (1973). Synthesis of prostaglandins by alanate additions to cyclopentenones (1). Prostaglandins. 3(6). 921–924. 10 indexed citations
17.
Floyd, M. Brawner & George R. Allen. (1970). Cyclic Analog of Ethacrynic Acid. Journal of Pharmaceutical Sciences. 59(6). 869–870.
18.
Gensler, Walter J., et al.. (1970). Synthesis of methyl sterculate. Journal of the American Chemical Society. 92(8). 2472–2475. 12 indexed citations
19.
Gensler, Walter J., et al.. (1970). Syntheses of methyl malvalate and methyl 5-6-methano-5-undecenoate. The Journal of Organic Chemistry. 35(7). 2301–2307. 10 indexed citations
20.
Wasserman, Harry H. & M. Brawner Floyd. (1963). On the autoxidation of indoles. Tetrahedron Letters. 4(29). 2009–2012. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026